Shionogi & Co. Ltd. has opened up its oral COVID-19 antiviral ensitrelvir (S-217622) to manufacture and supply by other producers to low- and middle-income countries around the world under a new voluntary licensing agreement with the Medicines Patent Pool (MPP).
Shionogi's Oral COVID Drug Set For Global Access Through MPP
Hot On Heels Of PIII Data
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
